Опухоли головы и шеи. 2022; 12: 109-115
Современные тенденции в лечении рецидивирующего аденокистозного рака слюнных желез: клинический случай
https://doi.org/10.17650/2222-1468-2022-12-4-109-115Аннотация
Рак слюнных желез представляет собой редкое злокачественное новообразование с различными гистологическими характеристиками и биологическим поведением. Режимы лечения данной патологии практически не менялись на протяжении десятилетий: в основном применяются хирургическое вмешательство и лучевая терапия. Особое место в опухолях этой локализации занимает аденокистозный рак, который в основном характеризуется рецидивирующим и / или метастатическим течением. Главной опцией в его лечении является химиотерапия. Стоит отметить, что применение стандартных схем химиотерапии показывает неудовлетворительные результаты: при рецидивирующем или метастатическом аденокистозном раке слюнных желез варианты лечения минимальны. В связи с этим существует необходимость изучения новых методов терапии данного заболевания. В такой ситуации большие надежды возлагают на таргетную терапию, в частности на применение семейства рецепторов эпидермального фактора роста и c-Kit, которые являются наиболее исследуемыми молекулярными мишенями. Из-за редкой встречаемости аденокистозного рака число случаев использования данного лечения относительно невелико, поэтому каждое клиническое наблюдение представляет особую ценность. В статье представлен клинический случай терапии рецидивирующего аденокистозного рака слюнных желез с применением персонализированного подхода.
Цель работы – описание клинического наблюдения применения таргетных препаратов при рецидивирующем или метастатическом аденокистозном раке слюнных желез.
Список литературы
1. Batsakis J.G., Regezi J.A. The pathology of head and neck tumors: salivary glands, part 1. Head Neck Surg 1978;1(1):59–68. DOI: 10.1002/hed.2890010109
2. Speight P.M., Barrett A.W. Salivary gland tumours. Oral Dis 2002;8(5):229–40. DOI: 10.1034/j.1601-0825.2002.02870.x
3. Al-Khateeb T.H., Ababneh K.T. Salivary tumors in north Jordanians: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(5):e53–9. DOI: 10.7417/CT.2021.2306
4. Carlson E.R., Ord R.A. Salivary gland pathology: diagnosis and management. John Wiley & Sons, 2015.
5. El-Naggar A.K., Chan J.K.C., Grandis J.R. et al. WHO classification of head and neck tumours. 4th ed. Vol.9. International Agency for Research on Cancer, 2017.
6. Lewis A.G., Tong T., Maghami E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 2016;49(2):343–80. DOI: 10.1016/j.otc.2015.11.001
7. Terhaard C.H., Lubsen H., Rasch C.R. et al. Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61(1):103–11. DOI: 10.1016/j.ijrobp.2004.03.018
8. Nam S.J., Roh J.L., Cho K.J. et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 2016;23(13):4376–83. DOI: 10.1245/s10434-016-5356-3
9. Laurie S.A., Ho A.L., Fury M.G. et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011;12(8):815–24. DOI: 10.1016/S1470-2045(10)70245-X
10. Ettl T., Schwarz-Furlan S., Gosau M., Reichert T.E. Salivary gland carcinomas. Oral Maxillofac Surg 2012;16(3):267–83. DOI: 10.1007/s10006-012-0350-9
11. Lin H.H., Limesand K.H., Ann D.K. Current state of knowledge on salivary gland cancers. Crit Rev Oncog 2018;23(3–4):139–51. DOI: 10.1615/CritRevOncog.2018027598
12. Li N., Xu L., Zhao H. et al. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer 2012;118(16):3945–53. DOI: 10.1002/cncr.26740
13. Jaso J., Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med 2011;135(4):511–5. DOI: 10.5858/2009-0527-RS.1
14. Khan A.J., DiGiovanna M.P., Ross D.A. et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001;96(3):149–58. DOI: 10.1002/ijc.1013
15. Dillon P.M., Chakraborty S., Moskaluk C.A. et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 2016;38(4):620–7. DOI: 10.1002/hed.23925
16. Roh J.L., Ryu C.H., Choi S.H. et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 2007;48(2):240–6. DOI: 10.1016/j.remn.2015.04.003
17. Nakamoto Y., Tatsumi M., Hammoud D. et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234(3):879–85. DOI: 10.1148/radiol.2343030301
18. Papaspyrou G., Hoch S., Rinaldo A. et al. Head Neck. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011;33(6):905–11. DOI: 10.1002/hed.21458
19. Besmer P., Murphy J.E., George P.C. et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320(6061):415–21. DOI: 10.1038/320415a0
20. Druker B.J., Talpaz M., Resta D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–7. DOI: 10.1056/NEJM200104053441401
21. Adelstein D.J., Koyfman S.A., El-Naggar A.K., Hanna E.Y. Biology and management of salivary gland cancers. Semin Radiat Oncol 2012;22(3):245–53. DOI: 10.1016/j.semradonc.2012.03.009
22. Bahl A., Panda N.K., Elangovan A. et al. (2018). Evaluation of multimodality management of adenoid cystic carcinoma of the head and neck. Indian J Otolaryngol Head Neck Surg 2019;71(Suppl. 1):628–32. DOI: 10.1007/s12070-018-1442-0
23. Hotte S.J., Winquist E.W., Lamont E. et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase II consortium study. J Clin Oncol 2005;23(3):585–90. DOI: 10.1200/JCO.2005.06.125
24. Sridharan V., Gjini E., Liao X. et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res 2016;4(8):679–87. DOI: 10.1158/2326-6066.CIR-16-0031
25. Cohen R.B., Delord J.-P., Doi T. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE028 study. Am J Clin Oncol 2018;41)11):1083–8. DOI: 10.1097/COC.0000000000000429
Head and Neck Tumors (HNT). 2022; 12: 109-115
Current trends in the treatment of recurrent adenocystic cancer of the salivary glands: case report
https://doi.org/10.17650/2222-1468-2022-12-4-109-115Abstract
Salivary gland carcinomas is a rare family of neoplasms with different histological characteristics and biological behavior. Treatment regimens have remained virtually unchanged for decades, leaving the leading role for surgical treatment and radiation therapy. However, a special place in the salivary gland carcinomas group is occupied by adenoid cystic carcinoma, which is quite often characterized by a recurrent and / or metastatic course with the use of chemotherapy as the main option in treatment. It is worth noting the fact that the results of standard chemotherapy regimens show unsatisfactory results, respectively, with recurrent or metastatic adenoid cystic carcinoma, treatment options are minimal. Accordingly, there is a need to study new therapeutic methods for the treatment of this disease. In this situation, high hopes were placed on targeted therapy, in particular, the family of epidermal growth factor receptors, c-Kit are the most frequently studied molecular targets. Due to the rare occurrence of adenoid cystic carcinoma, the number of cases of using targeted therapy for analysis is relatively small, so each clinical observation is of particular value. The following is a clinical case of treatment of recurrent adenoid cystic carcinoma using a personalized treatment approach.
Aim. To describe the clinical observation of the use of targeted drugs in recurrent or metastatic adenocystic cancer of the salivary glands.
References
1. Batsakis J.G., Regezi J.A. The pathology of head and neck tumors: salivary glands, part 1. Head Neck Surg 1978;1(1):59–68. DOI: 10.1002/hed.2890010109
2. Speight P.M., Barrett A.W. Salivary gland tumours. Oral Dis 2002;8(5):229–40. DOI: 10.1034/j.1601-0825.2002.02870.x
3. Al-Khateeb T.H., Ababneh K.T. Salivary tumors in north Jordanians: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(5):e53–9. DOI: 10.7417/CT.2021.2306
4. Carlson E.R., Ord R.A. Salivary gland pathology: diagnosis and management. John Wiley & Sons, 2015.
5. El-Naggar A.K., Chan J.K.C., Grandis J.R. et al. WHO classification of head and neck tumours. 4th ed. Vol.9. International Agency for Research on Cancer, 2017.
6. Lewis A.G., Tong T., Maghami E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 2016;49(2):343–80. DOI: 10.1016/j.otc.2015.11.001
7. Terhaard C.H., Lubsen H., Rasch C.R. et al. Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61(1):103–11. DOI: 10.1016/j.ijrobp.2004.03.018
8. Nam S.J., Roh J.L., Cho K.J. et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 2016;23(13):4376–83. DOI: 10.1245/s10434-016-5356-3
9. Laurie S.A., Ho A.L., Fury M.G. et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011;12(8):815–24. DOI: 10.1016/S1470-2045(10)70245-X
10. Ettl T., Schwarz-Furlan S., Gosau M., Reichert T.E. Salivary gland carcinomas. Oral Maxillofac Surg 2012;16(3):267–83. DOI: 10.1007/s10006-012-0350-9
11. Lin H.H., Limesand K.H., Ann D.K. Current state of knowledge on salivary gland cancers. Crit Rev Oncog 2018;23(3–4):139–51. DOI: 10.1615/CritRevOncog.2018027598
12. Li N., Xu L., Zhao H. et al. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer 2012;118(16):3945–53. DOI: 10.1002/cncr.26740
13. Jaso J., Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med 2011;135(4):511–5. DOI: 10.5858/2009-0527-RS.1
14. Khan A.J., DiGiovanna M.P., Ross D.A. et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001;96(3):149–58. DOI: 10.1002/ijc.1013
15. Dillon P.M., Chakraborty S., Moskaluk C.A. et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 2016;38(4):620–7. DOI: 10.1002/hed.23925
16. Roh J.L., Ryu C.H., Choi S.H. et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 2007;48(2):240–6. DOI: 10.1016/j.remn.2015.04.003
17. Nakamoto Y., Tatsumi M., Hammoud D. et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234(3):879–85. DOI: 10.1148/radiol.2343030301
18. Papaspyrou G., Hoch S., Rinaldo A. et al. Head Neck. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011;33(6):905–11. DOI: 10.1002/hed.21458
19. Besmer P., Murphy J.E., George P.C. et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320(6061):415–21. DOI: 10.1038/320415a0
20. Druker B.J., Talpaz M., Resta D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–7. DOI: 10.1056/NEJM200104053441401
21. Adelstein D.J., Koyfman S.A., El-Naggar A.K., Hanna E.Y. Biology and management of salivary gland cancers. Semin Radiat Oncol 2012;22(3):245–53. DOI: 10.1016/j.semradonc.2012.03.009
22. Bahl A., Panda N.K., Elangovan A. et al. (2018). Evaluation of multimodality management of adenoid cystic carcinoma of the head and neck. Indian J Otolaryngol Head Neck Surg 2019;71(Suppl. 1):628–32. DOI: 10.1007/s12070-018-1442-0
23. Hotte S.J., Winquist E.W., Lamont E. et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase II consortium study. J Clin Oncol 2005;23(3):585–90. DOI: 10.1200/JCO.2005.06.125
24. Sridharan V., Gjini E., Liao X. et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res 2016;4(8):679–87. DOI: 10.1158/2326-6066.CIR-16-0031
25. Cohen R.B., Delord J.-P., Doi T. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE028 study. Am J Clin Oncol 2018;41)11):1083–8. DOI: 10.1097/COC.0000000000000429
